Mexico
· Delayed Price · Currency is MXN BioCryst Pharmaceuticals Statistics
Total Valuation
BMV:BCRX has a market cap or net worth of MXN 42.49 billion. The enterprise value is 52.98 billion.
| Market Cap | 42.49B |
| Enterprise Value | 52.98B |
Important Dates
The last earnings date was Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 209.25M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.50% |
| Shares Change (QoQ) | +3.80% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 195.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 32.06 |
| PS Ratio | 4.13 |
| PB Ratio | -4.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 67.91, with an EV/FCF ratio of -96.42.
| EV / Earnings | -48.48 |
| EV / Sales | 5.36 |
| EV / EBITDA | 67.91 |
| EV / EBIT | 78.34 |
| EV / FCF | -96.42 |
Financial Position
The company has a current ratio of 2.93
| Current Ratio | 2.93 |
| Quick Ratio | 2.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | 20.87 |
| Debt / FCF | -30.85 |
| Interest Coverage | 0.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 4.54% |
| Return on Invested Capital (ROIC) | 5.71% |
| Return on Capital Employed (ROCE) | 10.12% |
| Revenue Per Employee | 17.74M |
| Profits Per Employee | -1.88M |
| Employee Count | 580 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 9.82 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +112.42% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +112.42% |
| 50-Day Moving Average | 256.19 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 51.85 |
| Average Volume (20 Days) | 394 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.99 |
Income Statement
In the last 12 months, BMV:BCRX had revenue of MXN 10.29 billion and -1.09 billion in losses. Loss per share was -5.30.
| Revenue | 10.29B |
| Gross Profit | 6.61B |
| Operating Income | 703.83M |
| Pretax Income | -1.05B |
| Net Income | -1.09B |
| EBITDA | 765.91M |
| EBIT | 703.83M |
| Loss Per Share | -5.30 |
Balance Sheet
The company has 6.03 billion in cash and 16.95 billion in debt, giving a net cash position of -10.92 billion.
| Cash & Cash Equivalents | 6.03B |
| Total Debt | 16.95B |
| Net Cash | -10.92B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -9.24B |
| Book Value Per Share | -44.15 |
| Working Capital | 5.52B |
Cash Flow
In the last 12 months, operating cash flow was -528.41 million and capital expenditures -21.09 million, giving a free cash flow of -549.50 million.
| Operating Cash Flow | -528.41M |
| Capital Expenditures | -21.09M |
| Free Cash Flow | -549.50M |
| FCF Per Share | n/a |
Margins
Gross margin is 64.25%, with operating and profit margins of 6.84% and -10.62%.
| Gross Margin | 64.25% |
| Operating Margin | 6.84% |
| Pretax Margin | -10.17% |
| Profit Margin | -10.62% |
| EBITDA Margin | 7.44% |
| EBIT Margin | 6.84% |
| FCF Margin | n/a |
Dividends & Yields
BMV:BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.50% |
| Shareholder Yield | -5.50% |
| Earnings Yield | -2.57% |
| FCF Yield | -1.29% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMV:BCRX has an Altman Z-Score of -2.24. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.24 |
| Piotroski F-Score | n/a |